LDL Lowering After Acute Coronary Syndrome: Is Lower Better?
- 6 November 2012
- journal article
- Published by Springer Nature in Current Treatment Options in Cardiovascular Medicine
- Vol. 15 (1) , 33-40
Abstract
Low density lipoprotein cholesterol (LDL-C) levels are a major risk factor for the development of acute coronary syndrome (ACS) and for recurrent events after ACS. Lowering LDL-C after ACS leads to a significant reduction in recurrent events and overall mortality. A lower limit at which LDL-C reduction fails to decrease risk has not been determined, and lowering LDL-C below current guideline-defined targets may provide incremental benefit. While the absolute risk is small, more intensive statin therapy is associated with a higher incidence of myopathy, rhabdomyolysis, liver enzyme abnormalities and incident diabetes, but not with an increase in malignancies or all-cause mortality. It is important that clinicians recognize ACS patients as being at very high risk, and provide these patients with intensive lifestyle and pharmacologic therapy for all modifiable risk factors. Within this framework, either a strategy of “intensive statin treatment after ACS” or a strategy of “aggressive LDL-C targets after ACS” would be appropriate based on currently available data. Combination lipid-lowering therapy does not have a firm evidence base at this point, but may be appropriate in patients with limited statin tolerance or very high baseline LDL-C levels. Newer therapies, such as LDL apheresis, antisense oligonucleotide sequences to apolipoprotein B (apoB) and preprotein convertase subtilin kexin 9 (PCSK9) inhibitors, are currently in clinical trials and may represent important advances in LDL-C lowering therapy in the future.Keywords
This publication has 38 references indexed in Scilit:
- European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)European Journal of Preventive Cardiology, 2012
- Statins and Intracerebral HemorrhageCirculation, 2011
- Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG)American Heart Journal, 2011
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- Immediate effect of intensive atorvastatin therapy on lipid parameters in patients with acute coronary syndromeLipids in Health and Disease, 2010
- Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trialsThe Lancet, 2010
- Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trialsHeart, 2007
- Statin Safety: A Systematic ReviewThe American Journal of Cardiology, 2006
- Effect of Statin Use Within the First 24 Hours of Admission for Acute Myocardial Infarction on Early Morbidity and Mortality††A complete list of participating hospitals is available from ClinTrials Research, 1100 Weston Parkway, Cary, North Carolina 27513.The American Journal of Cardiology, 2005
- Optimal low-density lipoprotein is 50 to 70 mg/dlJACC, 2004